FDA Class II Recall: Resource Recovery & Trading LLC's Hand Sanitizer Pulled Due to cGMP Deviations
RESOURCE RECOVERY & TRADING LLC initiated a Class II recall for 115 bottles of HAND SANITIZER Non-sterile Solution 70% Topical Solution due to cGMP deviations. This event, impacting distribution in AL and GA, underscores critical supply chain and regulatory risks for procurement directors and regulatory affairs heads sourcing drug products, even from distributors.
FDA Identifies cGMP Deviations in Resource Recovery & Trading LLC's Hand Sanitizer Recall
RESOURCE RECOVERY & TRADING LLC has initiated a Class II recall, designated D-1549-2020, for its HAND SANITIZER Non-sterile Solution 70% Topical Solution. The primary driver for this action, which commenced on July 27, 2020, was identified as deviations from current Good Manufacturing Practices (cGMP). This recall involved 115 bottles of the product, packaged in 20L (5.28 Gal) plastic containers, affecting all lots distributed by the firm. For procurement directors and regulatory affairs heads, this event highlights the critical importance of cGMP adherence across the entire supply chain, extending beyond primary manufacturers to distributors. Non-compliance with cGMP standards can compromise product quality, safety, and efficacy, leading to significant commercial disruption and potential public health risks. A Class II classification indicates that the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. This necessitates immediate action from any entity that may have sourced this specific product, requiring a thorough review of inventory and distribution channels to ensure removal and compliance.
Resource Recovery & Trading LLC: Distributor Profile and Product Scope
RESOURCE RECOVERY & TRADING LLC, based at 4275 Executive Square, Ste. 200, La Jolla, CA 92037-1476, operates as a distributor of drug products. The recalled item, HAND SANITIZER Non-sterile Solution 70% Topical Solution, falls under the 'Drugs' product type, underscoring the stringent regulatory expectations even for seemingly ubiquitous products. While the firm's specific manufacturing capabilities are not detailed in the recall notice, its role as a distributor means that any cGMP deviations could originate either from its own handling, storage, or labeling practices, or from the upstream manufacturer it sourced from. For supply chain VPs and business development executives, this distinction is crucial: due diligence must extend to all partners in the supply chain, including distributors, to ensure that cGMP compliance is maintained throughout the product's journey to market. Relying solely on a manufacturer's compliance without vetting distribution partners introduces an avoidable layer of risk, potentially exposing downstream formulators and end-users to non-compliant products.
Supply Chain Exposure: Regional Impact in Alabama and Georgia
The distribution pattern for the recalled HAND SANITIZER Non-sterile Solution 70% Topical Solution was limited to Alabama (AL) and Georgia (GA). While the quantity of 115 bottles may appear modest, the implications for regional procurement and supply chain management are significant. Any healthcare facilities, retail outlets, or industrial users in these states that procured this specific hand sanitizer are directly exposed to the cGMP compliance risks identified by the FDA. This regional focus emphasizes that even localized distribution networks are subject to rigorous federal oversight and can trigger recalls with commercial consequences. Procurement directors operating within these geographies must immediately verify their inventory and supplier records for this product. Furthermore, this incident serves as a reminder that the perceived low-risk nature of a product like hand sanitizer does not diminish the regulatory burden or the potential for supply chain disruption when cGMP standards are not met. The recall, initiated via a press release, highlights the firm's voluntary action, yet the underlying cGMP issues demand a proactive response from all affected parties.
Mitigating cGMP Risks: Proactive Supplier Qualification and Diversification Strategies
Given the cGMP deviations identified in the RESOURCE RECOVERY & TRADING LLC recall, procurement teams must reinforce their supplier qualification and diversification strategies. While specific alternative suppliers for this product are not detailed in the available intelligence, the broader industry context underscores the persistent challenges in maintaining cGMP integrity. Recent parallel events, such as Advanced Nutriceuticals' recall of BPC-157 due to sterility lapses, Real Clean Distribuciones SA de CV's hand sanitizer recall for methanol contamination, and AVKARE Inc.'s Dutasteride recall due to impurity failures, illustrate a pervasive pattern of cGMP-related risks across diverse drug products. These incidents, alongside Teva's Metformin recall for NDMA contamination and Assurance Infusion's LIPO B sterility breach, collectively highlight the critical need for robust vendor management. Procurement directors should prioritize suppliers with transparent quality systems, conduct regular audits, and seek geographic diversification to minimize reliance on single points of failure. This proactive approach is essential to safeguard supply chain resilience and ensure continuous access to compliant, high-quality drug products, including critical hygiene items like hand sanitizer.
Post-Recall Remediation and Sustained Regulatory Compliance Expectations
The recall initiated by RESOURCE RECOVERY & TRADING LLC for its HAND SANITIZER Non-sterile Solution 70% Topical Solution has been classified as 'Completed' by the FDA as of August 27, 2020. This status indicates that the firm has effectively removed the product from the market and distribution channels. However, the 'completed' status for the recall itself does not absolve the firm of its responsibility to address the root causes of the cGMP deviations. Regulatory affairs heads must understand that the FDA expects comprehensive corrective and preventive actions (CAPA) to be implemented to prevent recurrence. This typically involves a thorough investigation into the manufacturing, testing, and distribution processes that led to the non-compliance. For other industry stakeholders, this event serves as a crucial reminder that even voluntary, firm-initiated recalls carry significant commercial and reputational implications. Supply chain VPs should ensure their internal systems are robust enough to quickly identify, isolate, and remove recalled products, while also evaluating their supplier base for any similar underlying cGMP vulnerabilities that could trigger future regulatory actions and supply disruptions.